This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
Discussing the epilepsy offerings from UCB (Vimpat, Keppra, Briviact, Nayzilam). - 2nd look
Ticker(s): UCBWho's the expert?
Institution: University of Pennsylvania
- Associate Professor of Neurology & Medical Director of the Epilepsy Monitoring Unit and Penn Epilepsy Surgical Program
- Currently manages 1000 adults with focal epilepsy.
- Research lab focuses on advancing the fields of invasive neurophysiology and neuroimaging to better localize epileptic networks in medication refractory epilepsy patients.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
